{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002661","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.199716+00:00","generated_at":"2026-05-27T03:44:57.638956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q3 revenue up 17.5% to $62.8M; core organic growth 13.2%","bullets":["Revenue $62.8M (+17.5% YoY); non-GAAP core organic revenue +13.2%.","GAAP net loss $(1.68M) ($0.31 diluted); non-GAAP AOI ex unusual items $14.79M (+13.3%).","All four divisions grew: BPD +31.3% core organic, CS +18.9%, SDC +8.2%, CG +1.9% (3rd consecutive sequential rise).","Repaid $9.4M debt in Q3; net leverage ratio 3.20x; targeting below 3.0x by Q2 2026.","GKE acquisition contributed 4.9% inorganic growth and exceeded first-year expectations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002661","json":"https://secwatch.observer/filing/0001437749-25-002661.json","markdown":"https://secwatch.observer/filing/0001437749-25-002661.md","text":"https://secwatch.observer/filing/0001437749-25-002661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774925002661/0001437749-25-002661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774925002661/mlab20250203_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:44:57.638956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}